Egetis Therapeutics AB
P0F
Company Profile
Business description
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
Contact
Grev Turegatan 11 C
Stockholm114 46
SWET: +46 86797210
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
40
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks
ASX share ticks all the popular thematic boxes
The shares are overvalued as investors are overly excited about defence and gold exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,151.80 | 0.10 | 0.00% |
| CAC 40 | 8,347.94 | 0.74 | 0.01% |
| DAX 40 | 25,333.38 | 87.28 | -0.34% |
| Dow JONES (US) | 49,191.99 | 398.21 | -0.80% |
| FTSE 100 | 10,174.99 | 37.64 | 0.37% |
| HKSE | 26,999.81 | 151.34 | 0.56% |
| NASDAQ | 23,709.87 | 24.03 | -0.10% |
| Nikkei 225 | 54,341.23 | 792.07 | 1.48% |
| NZX 50 Index | 13,757.71 | 101.66 | 0.74% |
| S&P 500 | 6,963.74 | 13.53 | -0.19% |
| S&P/ASX 200 | 8,820.60 | 1.20 | -0.01% |
| SSE Composite Index | 4,126.09 | 12.67 | -0.31% |